Abstract：【Objective】 To investigate the influences of Xianling Gubao capsule combined with estrogen replacement therapy on the clinical symptoms, bone density and serum follicle stimulating hormone (FSH) and luteinizing hormone (LH) in perimenopausal syndrome patients. 【Methods】 Eighty-two cases of patients with perimenopausal syndrome in our hospital from August 2016 to August 2017 were selected. Patients were divided into the observation group and the control group by random alphabet. The control group was treated with estrogen replacement therapy, while the observation group was treated with Xianling Gubao capsule in addition to estrogen replacement. The therapeutic effect, adverse reactions and clinical symptoms improvement of the two groups were compared The bone mineral density and serum FSH, LH and estradiol (E2) levels were measured and compared before and after treatment. 【Results】 The effective rate of the observation group was 97.56% (40/41), which was significantly higher than 80.49% (33/41) of the control group (P<0.05). Kupperman score of the observation group was significantly lower than that of the control group, and the difference was statistically significant (P<0.05). Compared to the control group, the mean vertebral bone density and mean femoral neck bone density were higher in the observation group (P<0.05). In comparison with the control group, the serum FSH and LH levels in the observation group were significantly decreased, while serum E2 level increased significantly (P<0.05); the incidence of adverse reactions in the observation group(4.88%) was significantly lower than that in the control group(24.39%), and the difference was statistically significant (P<0.05). 【Conclusion】 The application of Xianling Gubao capsule combined with estrogen replacement therapy has achieved satisfactory clinical effect in the treatment of perimenopausal syndrome, which clinical symptoms are relieved, bone density is increased significantly, the levels of serum FSH and LH are improved. It can promote the effective recovery of ovarian function, at the same time, there was no obvious adverse reaction.
2020, Vol. 37 
